Patent assignee · FR · COMPANY

OBE THERAPY BIOTECHNOLOGY

2Patents
1Active
2Granted
28Portfolio score

Filing activity: Jun 29, 2000 → Dec 16, 2013

Most-cited patents

PatentTitleAreaCited byStatus
US6942967B1 Target for treating athersclerosis, obesity and type II diabetes Human Necessities 2 Expired
US9481709B2 Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism Human Necessities 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.